Abstract
A conspicuous feature shared by Alzheimers disease as well as a variety of highly prevalent, clinically unrelated neurodegenerative disorders is the occurrence of protein aggregates both intra- and extracellularly. Most of these conditions are characterized at autopsy by the presence of such deposits, typically of fibrillar structure and accompanying extensive neuronal cell loss, displaying a selective brain distribution. The recently discovered similarities of a number of these aggregates with a novel type of experimentally induced protein deposit, formed as a general response to discrepancies in protein turnover and designated the “aggresome”, has prompted speculations about the involvement of the ubiquitin-proteasome system in a process fundamental to neurodegeneration. Consistent with this view, protein aggregates have been regarded in a pathogenic connotation, with most aspects of neurologic pathogenesis being largely attributed to their presence in nerve tissues. However, the neurotoxicity of protein aggregates remains ambiguous as direct evidence substantiating it have long remained elusive. A convergence of evidence now support the notion that the actual culprits might comprise the oligomeric, non-fibrillar intermediates that arise early during the aggregation process, termed protofibrils and that the fibrillar end-stage aggregates themselves might actually serve a neuroprotective function. These intermediates ostensibly resolve many puzzling aspects of neurodegeneration and there is evidence that neurotoxicity is one key operational property they may possess. The above attest to the fact that protein aggregation remains a complex issue with a role far more enigmatic than originally thought but nonetheless important for the understanding of the pathological basis of neurodegenerative disorders.
Keywords: ad, sp, nft, aggregate, homeostasis, ros, ups, aggresome
Current Alzheimer Research
Title: Protein Aggregation in Alzheimers Disease and Other Neoropathological Disorders
Volume: 2 Issue: 1
Author(s): Aristotelis C. Dimakopoulos
Affiliation:
Keywords: ad, sp, nft, aggregate, homeostasis, ros, ups, aggresome
Abstract: A conspicuous feature shared by Alzheimers disease as well as a variety of highly prevalent, clinically unrelated neurodegenerative disorders is the occurrence of protein aggregates both intra- and extracellularly. Most of these conditions are characterized at autopsy by the presence of such deposits, typically of fibrillar structure and accompanying extensive neuronal cell loss, displaying a selective brain distribution. The recently discovered similarities of a number of these aggregates with a novel type of experimentally induced protein deposit, formed as a general response to discrepancies in protein turnover and designated the “aggresome”, has prompted speculations about the involvement of the ubiquitin-proteasome system in a process fundamental to neurodegeneration. Consistent with this view, protein aggregates have been regarded in a pathogenic connotation, with most aspects of neurologic pathogenesis being largely attributed to their presence in nerve tissues. However, the neurotoxicity of protein aggregates remains ambiguous as direct evidence substantiating it have long remained elusive. A convergence of evidence now support the notion that the actual culprits might comprise the oligomeric, non-fibrillar intermediates that arise early during the aggregation process, termed protofibrils and that the fibrillar end-stage aggregates themselves might actually serve a neuroprotective function. These intermediates ostensibly resolve many puzzling aspects of neurodegeneration and there is evidence that neurotoxicity is one key operational property they may possess. The above attest to the fact that protein aggregation remains a complex issue with a role far more enigmatic than originally thought but nonetheless important for the understanding of the pathological basis of neurodegenerative disorders.
Export Options
About this article
Cite this article as:
Dimakopoulos C. Aristotelis, Protein Aggregation in Alzheimers Disease and Other Neoropathological Disorders, Current Alzheimer Research 2005; 2 (1) . https://dx.doi.org/10.2174/1567205052772795
DOI https://dx.doi.org/10.2174/1567205052772795 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer’s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Toxicity of Carbon Nanotubes
Current Drug Metabolism HTLV-1 Associated Neurological Disorders
Current Topics in Medicinal Chemistry Multifunctional Ligands in Medicinal Inorganic Chemistry- Current Trends and Future Directions
Current Topics in Medicinal Chemistry Stem Cells for the Treatment of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Mesenchymal Stem Cells Neuronal Differentiation Ability: A Real Perspective for Nervous System Repair?
Current Stem Cell Research & Therapy Nerve Growth Factor: A Focus on Neuroscience and Therapy
Current Neuropharmacology Cell Therapies for IBD: What Works?
Current Drug Targets Neurogenesis and Stroke
CNS & Neurological Disorders - Drug Targets Conference Report (42nd Annual Meeting of the Italian Society of Neurology, 22-25 October 2011, Turin, Italy)
CNS & Neurological Disorders - Drug Targets Neurogenesis and Sensorimotor Gating: Bridging a Microphenotype and an Endophenotype
Current Molecular Medicine Nanostructured Lipid Carriers (NLCs) for Drug Delivery and Targeting
Recent Patents on Nanotechnology Regression of Oxidative Stress by Targeting eNOS and Nrf2/ARE Signaling: A Guided Drug Target for Cardiovascular Diseases
Current Topics in Medicinal Chemistry GDNF Family Ligands: A Potential Future for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Editorial (Hot Topic: Mitochondrion: An Organelle More and More Implication in New Processes)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Berberine Nanoencapsulation Attenuates Hallmarks of Scoplomine Induced Alzheimer's-Like Disease in Rats
Current Reviews in Clinical and Experimental Pharmacology Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR, AMPK, and Erythropoietin
Current Neurovascular Research Role of Circular RNAs in Prostate Cancer
Current Medicinal Chemistry High Fat Meal Increase of IL-17 is Prevented by Ingestion of Fruit Juice Drink in Healthy Overweight Subjects
Current Pharmaceutical Design Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease
Current Pharmaceutical Design